Leal Therapeutics

What Leal Therapeutics does

Leal Therapeutics is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in Worcester, Massachusetts. The company develops first-in-class neuro-metabolic therapeutics that target metabolic imbalances underlying central nervous system (CNS) disorders with high unmet need, including schizophrenia, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, bipolar disorder, major depressive disorder, and obesity/metabolic syndrome. Its pipeline comprises four named programs: LTX-001, a brain-penetrant oral glutaminase (GLS1) inhibitor entering Phase 1b/2a for schizophrenia; LTX-002, an intrathecally delivered antisense oligonucleotide (ASO) targeting SPTLC1 in Phase 1/2 for genetic and sporadic ALS (NeurALS trial); LTX-007, a small-molecule SPT inhibitor at candidate-selection stage for Alzheimer's disease and rare CNS sphingolipidoses; and LTX-008, a small-molecule SPT inhibitor at candidate-selection stage for obesity/metabolic syndrome. The company also operates a next-generation antibody-like shuttle platform for peripheral-to-CNS delivery across the blood-brain barrier, applicable across the pipeline.

Leal's discovery engine is grounded in human genetics, human biomarker data, and preclinical model data rather than purely symptomatic pharmacology. The company employs two therapeutic modalities — brain-penetrant oral small molecules (LTX-001, LTX-007, LTX-008) and CNS-administered antisense oligonucleotides (LTX-002) — with delivery via oral administration, intrathecal injection, or its proprietary BBB shuttle. Key differentiating product propositions include LTX-001's potential to address positive, negative, and cognitive symptoms of schizophrenia without sedation or movement-disorder side effects and with metabolic benefits (weight loss or neutrality), and LTX-002's positioning to serve the broader ALS population beyond the <2% of patients with SOD1 mutations who benefit from Qalsody.

Leal is pre-revenue and pre-commercial; it has raised approximately $114 million in cumulative disclosed funding (a previously disclosed $39 million, $45 million in October 2024 led by Newpath Partners, and a $30 million Series A in August 2025 led by SV Health Investors' Dementia Discovery Fund). The company plans to commercialize through partnering and/or independent commercialization upon regulatory approval. Its distribution model for clinical trials is direct administration at specialized trial sites (intrathecal for LTX-002, oral for LTX-001). Key investors include OrbiMed, Newpath Partners, SV Health Investors/DDF, Chugai Venture Fund, Alexandria Venture Investments, Euclidean Capital, and PhiFund; board representation includes Carl Gordon and Mona Ashiya (OrbiMed), Thomas Cahill (Newpath), Christian Jung (SV Health/DDF), Athena Countouriotis (Chair), and Franz Hefti (independent director). The senior team is led by founder/CEO Asa Abeliovich (who previously founded Prevail Therapeutics, acquired by Eli Lilly for ~$1B in 2021), with CMO Johannes Tauscher (ex-Takeda, ex-Eli Lilly), CTO Eduardo Paredes, and CBO Raymond Jordt (ex-Altimmune, ex-Eli Lilly).

Name

Leal Therapeutics

Legal name

Leal Therapeutics, Inc.

Website

https://lealtx.com/

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Leal Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class neuro-metabolic therapeutics — brain-penetrant small molecules, CNS antisense oligonucleotides, and a BBB shuttle delivery platform — for schizophrenia, ALS, Alzheimer's, and obesity.

Ownership category

akta.pro rank

Product category

CNS Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown) (HLAAADAC)

akta.pro secondary industries

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Neuro-metabolic therapeutics
• CNS drug development
• Antisense oligonucleotides
• Brain-penetrant small molecules
• Central nervous system disorders

Headquarters

HQ city

Worcester

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical product revenues: Pre-revenue clinical-stage company. Future revenues expected from commercialization of neuro-metabolic therapeutic pipeline (LTX-001, LTX-002, LTX-007, LTX-008) for CNS disorders including schizophrenia, ALS, Alzheimer's disease, and obesity/metabolic syndrome.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Leal Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class neuro-metabolic therapeutics for CNS disorders with high unmet need. The company develops brain-penetrant oral small molecules and intrathecally delivered antisense oligonucleotides (ASOs) targeting metabolic imbalances underlying schizophrenia, ALS, Alzheimer's disease, and obesity/metabolic syndrome. Its pipeline includes LTX-001 (GLS1 inhibitor), LTX-002 (SPTLC1-targeted ASO), LTX-007, and LTX-008, supported by a next-generation antibody-like BBB shuttle delivery platform.

Product overview

Leal Therapeutics is developing a pipeline of neuro-metabolic therapeutics addressing CNS disorders with high unmet need. The company's portfolio includes four named drug programs: LTX-001 (brain-penetrant oral GLS1 inhibitor for schizophrenia, entering Phase 1b/2a), LTX-002 (intrathecal ASO targeting SPTLC1 for ALS, in Phase 1/2), LTX-007 (brain-penetrant SPT inhibitor for Alzheimer's disease, at candidate-selection stage), and LTX-008 (oral SPT inhibitor for obesity/metabolic syndrome, at candidate-selection stage). Programs leverage two therapeutic modalities—small molecules and antisense oligonucleotides—with delivery approaches including oral administration, intrathecal delivery, and a next-generation antibody-like shuttle platform for CNS penetration.

Differentiator

Problem solved

Functional benefit

Products and services

• LTX-001 First-in-class brain-penetrant oral small molecule glutaminase (GLS1) inhibitor designed to restore glutamine-glutamate balance in the CNS for treatment of schizophrenia, bipolar disorder, major depressive disorder, and ALS. Currently in Phase 1/2a clinical development.
• LTX-002 First-in-class intrathecally delivered antisense oligonucleotide (ASO) targeting SPTLC1 to reduce excessive serine palmitoyltransferase activity and restore healthy sphingolipid levels for treatment of genetic and sporadic ALS. In Phase 1/2 clinical development.
• LTX-007 Brain-penetrant oral small molecule SPT inhibitor at candidate-selection stage for Alzheimer's disease and rare CNS sphingolipid disorders.
• LTX-008 Oral small molecule SPT inhibitor at candidate-selection stage for obesity/metabolic syndrome with potential for metabolic disease benefit and weight loss maintenance.
• Antibody-like Shuttle Technology Next-generation delivery platform utilizing antibody-like shuttle technology to enable transport of peripherally administered therapeutics across the blood-brain barrier to maximize target engagement in the CNS.

Quantifiable outcome

• LTX-001 completed single ascending dose clinical trial demonstrating safety and CNS target engagement with dose-dependent response
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Alector: Clinical-stage CNS biotech developing immuno-neurology therapeutics for neurodegenerative diseases, founded with overlapping leadership with Leal (Asa Abeliovich co-founded Alector). Comparable in stage, CNS focus, and platform approach.
• Sage Therapeutics: CNS-focused biopharmaceutical company developing first-in-class therapeutics for depression and neurological disorders. Direct peer in CNS specialty pharma with similar genetics-led approach and partnering-driven model (Zurzuvae partnership with Biogen).
• Karuna Therapeutics: Developed first-in-class schizophrenia therapy Cobenfy (xanomeline-trospium), acquired by Bristol-Myers Squibb for ~$14B. Direct peer in CNS specialty pharma with first-in-class mechanism approach; competitor to LTX-001 in schizophrenia.
• Cerevel Therapeutics: CNS-focused biopharma developing therapeutics for neuroscience diseases including schizophrenia and Parkinson's. Acquired by AbbVie for ~$8.7B; directly comparable to Leal's CNS specialty pharmaceutical positioning.
• Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative diseases with a strong BBB delivery and lysosomal biology focus. Comparable in CNS modality mix and platform approach to Leal's sphingolipid and BBB shuttle programs.
• Wave Life Sciences: Clinical-stage RNA therapeutics company developing stereopure oligonucleotides for CNS diseases including ALS and Huntington's. Comparable in ASO modality and CNS indication focus.

Broad incumbents

• Ionis Pharmaceuticals: Established leader in antisense oligonucleotide (ASO) drug development, co-developed Qalsody with Biogen for SOD1 ALS and Spinraza. Direct comparator for Leal's LTX-002 ASO program and broader ASO platform capabilities.
• Acadia Pharmaceuticals: Specialty CNS biopharma with commercial CNS products (Nuplazid, Daybue). Comparable as a CNS specialty pharma with neurodegenerative and neuropsychiatric focus, illustrating the commercial path for a late-stage CNS drug developer.
• Biogen: Large biopharma with a deep CNS franchise including Spinraza, Qalsody and Zurzuvae. Qalsody (intrathecal SOD1 ASO) is the most direct comparator to Leal's LTX-002 program in ALS.

Others

• Prevail Therapeutics: Gene therapy company for neurodegenerative diseases, founded by Leal's CEO Asa Abeliovich and acquired by Eli Lilly for ~$1B in 2021. Closely comparable via founder lineage and CNS modality focus, though now an Eli Lilly subsidiary.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Leal Therapeutics